Jazz Pharmaceuticals' Ziihera Gets FDA Priority Review for First-Line HER2+ Cancer Treatment

Key Takeaways

• FDA grants Priority Review for Jazz Pharmaceuticals’ supplemental Biologics License Application for Ziihera (zanidatamab-hrii) combinations
• Treatment targets first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma in adult patients
• PDUFA action date set for August 25, 2026, with expedited 6-month review timeline due to Priority Review designation

---

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced April 27, 2026, that the U.S. Food and Drug Administration has accepted its supplemental Biologics License Application (sBLA) for Ziihera® (zanidatamab-hrii) combinations with Priority Review designation. The application seeks approval for first-line treatment of adult patients with HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma.

Accelerated Review Timeline

The FDA’s Priority Review designation reduces the standard review timeline from 10 months to 6 months, with a Prescription Drug User Fee Act (PDUFA) target action date of August 25, 2026. This expedited timeline reflects the FDA’s recognition of Ziihera’s potential to address significant unmet medical needs in HER2-positive cancer treatment.

Market Impact and Treatment Landscape

Ziihera represents a bispecific antibody targeting two distinct epitopes on the HER2 receptor, offering a differentiated mechanism of action compared to existing HER2-targeted therapies. The first-line indication, if approved, would position Ziihera as a frontline treatment option for patients with HER2-positive gastroesophageal adenocarcinoma, a patient population with limited therapeutic options.

Clinical Development Progress

The sBLA submission is supported by clinical trial data demonstrating Ziihera’s efficacy and safety profile in combination regimens. Jazz Pharmaceuticals has been advancing Ziihera through multiple clinical studies across various HER2-positive cancer indications, with this first-line gastroesophageal adenocarcinoma application representing a key regulatory milestone.

Commercial Implications

Approval would expand Ziihera’s commercial footprint in the competitive HER2-targeted oncology market. The first-line indication could significantly impact treatment paradigms and provide Jazz Pharmaceuticals with a stronger position in the precision oncology space, particularly given the growing emphasis on biomarker-driven cancer therapies.

---

Frequently Asked Questions

What does Priority Review mean for Ziihera’s approval timeline?

Priority Review reduces FDA’s standard review time from 10 months to 6 months, with a target decision date of August 25, 2026. This designation is reserved for treatments that could provide significant improvements over existing therapies.

When will Ziihera be available for first-line HER2+ cancer treatment?

If approved, Ziihera could be available by late August 2026. However, FDA approval is not guaranteed, and the agency may request additional information or studies before making a final decision.

How does Ziihera differ from existing HER2-targeted cancer treatments?

Ziihera is a bispecific antibody that targets two different sites on the HER2 receptor simultaneously, potentially offering enhanced efficacy compared to traditional HER2-targeted monoclonal antibodies that bind to a single epitope.